SAN DIEGO, April 11, 2022 /PRNewswire/ — Aviva Systems Biologya market leader in antibodies, immunoassay kits and recombinant proteins for life science research, today announced the launch of its new high-throughput service offering Antibody Characterization Services.
Aviva Systems Biology’s antibody characterization services offer drug discovery researchers in small to mid-sized biotechnology an affordable and easily accessible solution for rapid therapeutic antibody screening, kinetic analysis, mapping and clustering. epitopes. By leveraging the advanced Carterra® LSA™ platform, Aviva can provide high-throughput SPR analysis for biotherapeutic antibody development on a scale that other screening vendors cannot match.
“Adding our antibody characterization services to our current custom protein, ELISA and antibody development offering will allow our customers to reduce the cost and time it takes to bring a new biotherapeutic molecule at the clinic. We are thrilled to offer this unique solution to biotherapeutic antibody researchers,” said Kevin Harveypresident of Aviva Systems Biology.
Learn more about Aviva’s antibody characterization services at the 2022 AACR Annual Meeting at New Orleans at booth #1951, April 10-13, 2022or by visiting avivasysbio.com.
About Aviva Systems Biology
Aviva Systems Biology, founded in 2002, is a global leader in the proteomics research market offering a broad portfolio of polyclonal and monoclonal antibodies, immunoassay kits, recombinant proteins and custom protein expression and antibody characterization for academic and biopharmaceutical researchers. Based at San Diego, Californiathe Aviva offering supports multiple applications such as Western blotting, IHC, ELISA and immunoprecipitation, while providing researchers with one of the largest target and species catalogs to choose from.
SOURCE Aviva Systems Biology